Claudio Cianferotti

Claudio Cianferotti

Auto-generated profile, based on publicly available information

Claudio Cianferotti

Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, 53100 Siena, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2021 in Chemical Communications
Verified
Journal Article
Open access
PDF file
CCClaudio Cianferotti
Claudio Cianferotti
VFValentina Faltoni
Valentina Faltoni
ECElena Cini
Elena Cini
EEElena Ermini
Elena Ermini
FMFrancesca Migliorini
Francesca Migliorini
GGGiuseppe Giannini
Giuseppe Giannini
Antitumor hydroxamates SAHA and Dacinostat have been linked to cetuximab and trastuzumab through a non-cleavable linker based on the p-mercaptobenzyl alcohol structure. These antibody drug conjugates (ADCs) were able to inhibit HDAC in several tumour cell lines. The cetuximab based ADCs block human lung adenocarcinoma cell proliferation, demonstrating that bioconjugation with antibodies is a suitable approach for targeted therapy based on hydroxamic acid-containing drugs. This work also shows that ADC-based delivery might be used to overcome the classical pharmacokinetic problems of hydroxamic acids.